Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
International Drug Pricing Transparency
14 July 2020
Join us on the 21st July between 15:00 – 16:30 BST as OHE experts discuss the economics, politics, and public policy of international drug pricing.
Victor R. Fuchs Award for 2020 Goes to Patricia Danzon
23 June 2020
The American Society of Health Economists (ASHEcon) announced Patricia Danzon as recipient of the 2020 Victor R. Fuchs Award. This is given to an economist making…
OHE Authors Develop a Supply and Demand Model of Pharmaceutical Markets to Set Cost-Effectiveness Thresholds to Maximise and Distribute Social Welfare
15 June 2020
OHE authors develop a supply and demand model of pharmaceutical markets to analyse the social welfare distribution between consumers (payers) and developers (industry) to set an…
Paying for Cures
12 May 2020
At a time when health systems had to shift their resources to deal with the COVID-19 crisis, it becomes more important than ever to find effective…
The Digitalisation of Health Care During COVID-19: Consideration of the Long-Term Consequences
28 April 2020
The need for social distancing in light of COVID-19 has led to an unprecedented increase in reliance on digital technologies by both health care providers and…
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support
14 April 2020
Research by OHE and the University of Washington into how uncertainty-related novel elements of value could be included in an Augmented Cost-Effectiveness Analysis has been published…
Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds
3 March 2020
OHE has published a white paper discussing the relative merits and shortfalls of current approaches to defining, estimating, and applying cost-effectiveness thresholds in HTA. This will…
Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation
21 February 2020
People living in Middle and Low Income Countries (MLICs) do not get access to innovative treatments and new treatments meeting MLIC requirements do not come to…
A Final MVAC Blueprint—and the Start of an R&D Revolution?
6 February 2020
TB kills 1.6m people annually – the world’s deadliest infectious disease. The Market-Driven, Value-Based Advance Commitment (MVAC), creates and guarantees a market for better TB treatment.…